Juicebox avatar

Dexa/Juicebox

Learn more
Published Dec 20, 2019

Dexcom CEO talks Servers, Control IQ and more

Dexcom CEO Kevin Sayer joins Scott Benner to delve into the pivotal advancements in diabetes technology, from the FDA's approval of Tandem's Control IQ system to partnerships with insulin leaders, while addressing community concerns over a recent CGM data-sharing outage and the company's strategies for future prevention.
Episode Highlights
Juicebox Podcast: Type 1 Diabetes logo

Topics covered

Popular Clips

Episode Highlights

  • Lily Partnership

    Dexcom's collaboration with Lily marks a significant step in insulin delivery innovation. explains that Lily is working on Bluetooth-connected insulin pens, which will provide data similar to insulin pumps, enhancing patient care. Dexcom will integrate its CGM technology into Lily's products, supporting their automated insulin delivery systems 1. This partnership highlights Dexcom's commitment to patient-centric solutions, as Kevin notes, "One of our mottos is, always, here, do right by the patients and the results will follow." 2

       

    Control IQ Approval

    The FDA's approval of Tandem's Control IQ system is a breakthrough in diabetes management. celebrates this development, emphasizing the importance of having another automated insulin delivery option for patients 3. Powered by Dexcom's G6 sensor, Control IQ offers stability and precision, as evidenced by user feedback showing stable glucose levels over 24 hours. Kevin praises Tandem's achievement, stating, "It's really good that we have another choice for patients. Kudos to Tandem and those guys."

Related Episodes